Promoter methylation blocks FES protein-tyrosine kinase gene expression in colorectal cancer

Genes Chromosomes and Cancer

Volumn 48, Issue 3, 2009, Pages 272-284

  Shaffer, Jonathan M ^a   Smithgall, Thomas E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; CPG OLIGODEOXYNUCLEOTIDE; DNA METHYLTRANSFERASE INHIBITOR; GENOMIC DNA; PROTEIN KINASE FES;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL STRAIN CACO 2; CELL STRAIN HCT116; COLORECTAL CANCER; DNA ISOLATION; DOWN REGULATION; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; METHYLATION; PRIORITY JOURNAL; TRANSCRIPTION INITIATION;

AZACITIDINE; BASE SEQUENCE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-FES;

EID: 62449123072     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20638     Document Type: Article

References (44)

1. Alcalay M, Antolini F, Van de Ven WJM, Lanfrancone L, Grignani F, Pelicci PG. 1990. Characterization of human and mouse c-fes cDNA clones and identification of the 5' end of the gene. Oncogene 5:267-275.
2. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S, Mar-kowitz S, Willson JK, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE. 2003. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300:949.
3. Baylin SB, Ohm JE. 2006. Epigenetic gene silencing in cancer-A mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6:107-116.
4. Boyes J, Bird A. 1991. DNA methylation inhibits transcription indirectly via a methyl-CpG binding protein. Cell 64:1123-1134.
5. Cheng HY, Rogers JA, Dunham NA, Smithgall TE. 1999. Regulation of c-Fes tyrosine kinase and biological activities by N-ter-minal coiled-coil oligomerization domains. Mol Cell Biol 19:8335-8343.
6. Cheng HY, Schiavone AP, Smithgall TE. 2001. A point mutation in the N-terminal coiled-coil domain releases c-Fes tyrosine ki-nase activity and survival signaling in myeloid leukemia cells. Mol Cell Biol 21:6170-6180.
7. Christman JK. 2002. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy. Oncogene 21:5483-5495.
8. Cross SH, Meehan RR, Nan X, Bird A. 1997. A component of the transcriptional repressor MeCP1 shares a motif with DNA methyltransferase and HRX proteins. Nat Genet 16:256-259.
9. Delfino FJ, Shaffer JM, Smithgall TE. 2006a. The KRAB-associ-ated co-repressor KAP-1 is a coiled-coil binding partner, substrate, and activator of the c-Fes protein-tyrosine kinase. Biochem J 399:141-150.
10. Delfino FJ, Stevenson HM, Smithgall TE. 2006b. A growth-sup-pressive function for the c-Fes protein-tyrosine kinase in colorectal cancer. J Biol Chem 281:8829-8835.
11. Fang JY, Lu J, Chen YX, Yang L. 2003. Effects of DNA methylation on expression of tumor suppressor genes and proto-onco-gene in human colon cancer cell lines. World J Gastroenterol 9:1976-1980.
12. Feldman RA, Lowy DR, Vass WC, Velu TJ. 1989. A highly efficient retroviral vector allows detection of the transforming activity of the human c-fpslfes proto-oncogene. J Virol 63:5469-5474.
13. Greer PA. 2002. Closing in on the biological functions of Fps/Fes and Fer. Nat Rev Mol Cell Biol 3:278-289.
14. Greer PA, Meckling-Hansen K, Pawson T. 1988. The human c-fpslfes gene product expressed ectopically in rat fibroblasts is nontransforming and has restrained protein-tyrosine kinase activity. Mol Cell Biol 8:578-587.
15. Greer P, Haigh J, Mbamalu G, Khoo W, Bernstein A, Pawson T. 1994. The Fps/Fes protein-tyrosine kinase promotes angiogene-sis in transgenic mice. Mol Cell Biol 14:6755-6763.
16. Haigh J, McVeigh J, Greer P. 1996. The Fps/Fes tyrosine kinase is expressed in myeloid, vascular endothelial, epithelial and neuronal cells and is localized to the trans-golgi network. Cell Growth Differentiation 7:931-944.
17. Harrington MA, Jones PA, Imagawa M, Karin M. 1988. Cytosine methylation does not affect binding of transcription factor Sp1. Proc Natl Acad Sci USA 85:2066-2070.
18. He Y, Borellini F, Koch WH, Huang K-X, Glazer RI. 1996. Tran-scriptional regulation of c-fes in myeloid leukemia cells. Biochim Biophys Acta 1306:179-186.
19. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB. 1995. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525-4530.
20. Herman JG, Baylin SB. 2003. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042-2054.
21. Heydemann A, Juang G, Hennessy K, Parmacek MS, Simon MC. 1996. The myeloid-cell-specific c-fes promoter is regulated by Sp1, PU1, and a novel transcription factor. Mol Cell Biol 16:1676-1686.
22. Heydemann A, Boehmler JH, Simon MC. 1997. Expression of two myeloid cell-specific genes requires the novel transcription factor, c-fes expression factor. J Biol Chem 272:29527-29537.
23. Holler M, Westin G, Jiricny J, Schaffner W. 1988. Sp1 transcription factor binds DNA and activates transcription even when the binding site is CpG methylated. Genes Dev 2:1127-1135.
24. Issa JP. 2000. The epigenetics of colorectal cancer. Ann NY Acad Sci 910:140-153.
25. Jones PA, Baylin SB. 2002. The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428.
26. Jones PA, Takai D. 2001. The role of DNA methylation in mammalian epigenetics. Science 293:1068-1070.
27. Kondo Y, Issa JP. 2004. Epigenetic changes in colorectal cancer. Cancer Metastisis Rev 23:29-39.
28. Lewis JD, Meehan RR, Henzel WJ, Maurer-Fogy I, Jeppesen P, Klein F, Bird A. 1992. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 69:905-914.
29. Lionberger JM, Smithgall TE. 2000. The c-Fes protein-tyrosine kinase suppresses cytokine-independent outgrowth of myeloid leukemia cells induced by Bcr-Abl. Cancer Res 60:1097-1103.
30. Lozzio BB, Lozzio CB, Bamberger EG, Feliu AS. 1981. A multi-potential leukemia cell line (K-562) of human origin. Proc Soc Exp Biol Med 166:546-550.
31. Meehan RR, Lewis JD, McKay S, Kleiner EL, Bird AP. 1989.Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs. Cell 58:499-507.
32. Mori Y, Cai K, Cheng Y, Wang S, Paun B, Hamilton JP, Jin Z, Sato F, Berki AT, Kan T, Ito T, Mantzur C, Abraham JM, Meltzer SJ. 2006. A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. Gastroenterology 131:797-808.
33. Nan X, Campoy FJ, Bird A. 1997. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88:471-481.
34. Pogribny IP, Pogribna M, Christman JK, James SJ. 2000. Single-site methylation within the p53 promoter region reduces gene expression in a reporter gene construct: possible in vivo relevance during tumorigenesis. Cancer Res 60:588-594.
35. Ray-Gallet D, Mao C, Tavitian A, Moreau-Gachelin F. 1995. DNA binding specificities of Spi-1/PU1 and Spi-B transcription factors and identification of a Spi-1/Spi-B binding site in the c-fes/c-fps promoter. Oncogene 11:303-313.
36. Rice P, Longden I, Bleasby A. 2000. EMBOSS: The European Molecular Biology Open Software Suite. Trends Genet 16:276-277.
37. Robertson KD, Jones PA. 1998. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol 18:6457-6473.
38. Rogers JA, Cheng HY, Smithgall TE. 2000. Src homology 2 domain substitution modulates the kinase and transforming activities of the Fes protein-tyrosine kinase. Cell Growth Differ 11:581-592.
39. Sangrar W, Zirgnibl RA, Gao Y, Muller WJ, Jia Z, Greer PA. 2005. An identity crisis for fps/fes: Oncogene or tumor suppressor? Cancer Res 65:3518-3522.
40. Smithgall TE, Johnston JB, Bustin M, Glazer RI. 1991. Elevated expression of the c-fes proto-oncogene in adult human myeloid leukemia cells in the absence of gene amplification. J Natl Cancer Inst 83:42-46.
41. Smithgall TE, Yu G, Glazer RI. 1988. Identification of the differentiation-associated p93 tyrosine protein kinase of HL-60 leukemia cells as the product of the human c-fes locus and its expression in myelomonocytic cells. J Biol Chem 263:15050-15055.
42. Smithgall TE, Rogers JA, Peters KL, Li J, Briggs SD, Lionberger JM, Cheng H, Shibata A, Scholtz B, Schreiner S, Dunham NA. 1998. The c-Fes family of protein-tyrosine kinases. Critical Rev Oncog 9:43-62.
43. Ushijima T. 2005. Detection and interpretation of altered methyl-ation patterns in cancer cells. Nat Rev Cancer 5:223-231.
44. Yu G, Smithgall TE, Glazer RI. 1989. K562 leukemia cells trans-fected with the human c-fes gene acquire the ability to undergo myeloid differentiation. J Biol Chem 264:10276-10281.